a103amendment1tothequali






    Quality Agreement Amendment    Document: QAA-Xeris  Amendment1  Revision: 00  Date: 05/11/21  Replaces: N/A  Page: 1 of 4      Pyramid Laboratories, Inc. CONFIDENTIAL  Amendment Quality Agreement QAA-XERIS Revision 03       Page 1 of 4        Quality Agreement History Page  by and between          Contractor Name: Pyramid Laboratories, Inc. (PLI)    And    Client: Xeris Pharmaceuticals, Inc.     Agreement Description:      Aseptic Drug Product Manufacturing  and Analytical Services        Brief description of Quality  Agreement revisions Section Number Effective Date Document No.  Update of Appendix 1 for  Contacts and Responsibilities Appendix 1 Effective as of last  signatory date  QAA-XERIS  Revision 03  





 






    Quality Agreement Amendment    Document: QAA-Xeris  Amendment1  Revision: 00  Date: 05/11/21  Replaces: N/A  Page: 2 of 4      Pyramid Laboratories, Inc. CONFIDENTIAL  Amendment Quality Agreement QAA-XERIS Revision 03       Page 2 of 4  First AMENDMENT    This First Amendment (the “First Amendment”) is entered into as of the Amendment  Effective Date (as defined below) by and between Pyramid Laboratories, Inc.  (“PYRAMID”) and Xeris Pharmaceuticals, Inc. (“XERIS”) for purposes of amending that  certain Quality Agreement dated November 16, 2016 (as amended and restated by that  certain Amendment and Restatement Agreement dated as of November 16, 2020, the  “Quality Agreement”) between the parties.    In consideration of the mutual covenants set first in this First Amendment, and other  good and valuable consideration, the parties hereby agree as follows:     1. Amendment Effective Date. The effective date of this Amendment shall be the  date of the last signature below (“Amendment Effective Date”).  This First  Amendment is in compliance with the terms of the Quality Agreement, including,  without limitation, Section 1.4 titled “Amendments to Quality Agreement” thereof.  2. Amendments. The Quality Agreement is hereby amended by deleting Appendix 1  thereto in its entirety and inserting in lieu thereof new Appendix 1 as set forth  below:    APPENDIX 1:  Contacts and Responsibilities  Position XERIS  PYRAMID Laboratories, Inc.  Contract Manager [***] [***]  Analytical [***] [***]  Manufacturing/CMC [***] [***]  Quality Assurance [***] [***]  Pharmaceutical Development [***] [***]  Product Distribution [***] [***]  Project Manager [***] [***]  





 






    Quality Agreement Amendment    Document: QAA-Xeris  Amendment1  Revision: 00  Date: 05/11/21  Replaces: N/A  Page: 3 of 4      Pyramid Laboratories, Inc. CONFIDENTIAL  Amendment Quality Agreement QAA-XERIS Revision 03       Page 3 of 4  Position XERIS  PYRAMID Laboratories, Inc.  Regulatory [***] [***]    Contact Information    PYRAMID Laboratories, Inc.       Phone Number: [***]    XERIS Pharmaceuticals, Inc.    Phone Number: [***]    NOTE:    1)    A designee may be assigned to specific projects by the responsible personnel.  2)    The designated representatives of each company will be responsible for the supply or receipt  of information and controlled documents.”    3. Ratification.  Except as provided herein, all other terms, conditions and  provisions of the Quality Agreement shall remain in full force and effect.  If there  is any inconsistency between the terms of this First Amendment and the Quality  Agreement, the terms of this First Amendment shall govern.  4. Governing Law.  Section 25.9 of the Commercial Supply Agreement dated May  1, 2018, as amended by that certain Amendment No. 1 dated September 1, 2018  shall apply to this First Amendment directly as if incorporated herein.  5. Counterparts.  This First Amendment may be executed by the parties in separate  counterparts, each of which when so executed and delivered shall be an original,  but all such counterparts shall together constitute one and the same instrument.  Delivery of an executed signature page of this First Amendment by email or  facsimile transmission shall be effective as delivery of a manually executed  counterpart hereof.      IN WITNESS WHEREOF, the parties intending to be bound by the terms and conditions  hereof have caused this First Amendment to be signed by their duly authorized  representatives.      





 






    Quality Agreement Amendment    Document: QAA-Xeris  Amendment1  Revision: 00  Date: 05/11/21  Replaces: N/A  Page: 4 of 4      Pyramid Laboratories, Inc. CONFIDENTIAL  Amendment Quality Agreement QAA-XERIS Revision 03       Page 4 of 4    Xeris Pharmaceuticals, Inc. Pyramid Laboratories, Inc.    Signature: /s/ Sheila Moran    Signature: /s/ Heba Mina    Name: Sheila Moran Name: Heba Mina  Title: Vice President Quality  Title: Sr. Director of Quality and Regulatory   Affairs  Date: 5/12/2021 Date: 5/12/2021